INVO Fertility, Inc. (IVF)
IVFNASDAQ-CMMedical/Dental Instruments
$2.40
-0.2200 (-8.40%) today
At the close, Nov 16, 4:00 PM ET. After hours $2.39 -0.42%
- Market cap
- $2.76m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $2.34 to $2.74
- 52-week range
- $1.59 to $91.60
- Average volume
- –
- Previous close
- $2.62
Earnings
Next report
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.76m | $1.58m | $2.02m | $2.17m |
| Gross profit | $629.0k | $537.0k | $728.0k | $763.0k |
| Operating income | -$1.64m | -$1.41m | -$1.59m | -$1.29m |
| Net income | -$4.31m | $2.01m | -$5.54m | $889.0k |
Last four quarters: revenue $7.53m, margin -92.3%, free cash flow –
News
8 latest- INVO Fertility Consensus Price Target Raised 300% to $81.60Fintel · Nov 1, 2026
- INVO Fertility To Implement 1-for-4 Reverse Stock Split RTTNews · Oct 28, 2026
- After-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Day RTTNews · Aug 17, 2026
- INVO Fertility Soars After Q2 Revenue Rises 17%; Swings To Profit RTTNews · Aug 17, 2026
- INVO Records Q1 Net Loss Of $5 Mln; Stock Down RTTNews · Jun 23, 2026
- INVO Fertility, Inc. Q1 Loss Drops RTTNews · Jun 22, 2026
- INVO Fertility (IVF) Price Target Increased by 400.00% to 20.40Fintel · Apr 9, 2026
- INVO Fertility Shares Surge On Patent Issuance For Modified INVOcell Device RTTNews · Feb 11, 2026
The company
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology ('ART') care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on U.S.-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization ('IVF') and the intravaginal culture ('IVC') procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- invobioscience.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.